Organization | Andover Eye Associates

Andover Eye Associates Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Andover MA United States (1978)

Organization Overview

First Clinical Trial

2009

NCT01013376

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Andover Eye | Andover Eye Associates | Andover Eye Associates; 138 Haverhill Street; Andover MA 01810

Active Ingredients

Drugs in Phase 4 Trials (1)

polyethylene glycol (1 trial)

Drugs in Phase 3 Trials (3)

sodium citrate (1 trial)

tetryzoline (1 trial)

Drugs in Phase 2 Trials (8)

axr-159 (1 trial)

dupilumab (dupixent) (1 trial)

pg101 (1 trial)

rx-10045 (2 trials)

tanfanercept (1 trial)

tavilermide (1 trial)

top1630 (1 trial)

xg-104 (1 trial)

Drugs in Phase 1 Trials (2)

hydralazine (apresoline) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 2)

Keratoconjunctivitis (Phase 2)

Keratoconjunctivitis Sicca (Phase 3)

Macular Degeneration (Phase 1)

Syndrome (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 14
# of Trial APIs: 14